Ushbu ishga iqtibos qilgan ishlar

2 ta ish

Ish: May statins and PCSK9 inhibitors be protective from COVID-19 in familial hypercholesterolemia subjects?

1. Analysis of influence of background therapy for comorbidities in the period before infection on the risk of the lethal COVID outcome. Data from the international ACTIV SARS-CoV-2 registry («Analysis of chronic non-infectious diseases dynamics after COVID-19 infection in adult patients SARS-CoV-2»)

   E. I. Tarlovskaya, A. G. Arutyunov, А. О. Конради +97

   MaqolaLong-Term Effects of COVID-19Kardiologiia20210 iqtibos

   ABIABI:AkademIndex/openalex/2021.article.000346

2. Nanoparticle-Based PCSK9 Inhibition in Viral Infections: Evaluating Clinical Limitations and Advancing Therapeutic Strategies

   Moeen F. Dababneh, Bahjat Alhasso, Abdulkareem Shareef +10

   MaqolaLipoproteins and Cardiovascular HealthJournal of Pharmaceutical Innovation20260 iqtibos

   ABIABI:AkademIndex/openalex/2026.article.013240